|
Genetic Analysis of Brain Tumors Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Genetic Analysis of Brain Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Genetic Analysis of Brain Tumors Clinical research trials and Genetic Analysis of Brain Tumors medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Genetic Analysis of Brain Tumors. Genetic Analysis of Brain Tumors Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Genetic Analysis of Brain Tumors clinical trial. Participants oftentimes recieve the finest healthcare available for their Genetic Analysis of Brain Tumors condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Analysis of Brain Tumors  Genetic Analysis of Brain Tumors
Genetic Analysis of Brain Tumors
For Condition: Glioma
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors. Tumor classification can help guide treatment, in part by predicting how aggressive a tumor may be. Gliomas are currently classified according to their grade (how quickly they may grow) and the type of cells they are composed of. This system, however, is not always accurate, and sometimes two tumors that appear to be identical under the microscope will have very different growth patterns and responses to treatment. The new classification system is based on tumor genes and proteins, and may be used in the future to better predict a given tumor's behavior and response to therapy. Patients with evidence of a primary brain tumor and patients with a known glioma who will be undergoing surgery to remove the tumor may participate in this study. A sample of tumor tissue removed in the course of a participant's normal clinical care will be used in this study for laboratory analysis of genes and chromosome abnormalities. A small blood sample will also be collected for genetic analysis. In addition, clinical information on patients' condition and response to treatment will be collected every 6 months over several years. This information will include findings from physical and neurologic examinations, radiographic findings, and response to therapy, including surgery, radiation and chemotherapy.
Details: Primary brain tumors are an increasingly important cause of cancer-related morbidity and mortality in this country. Little progress has been made in the treatment of patients with gliomas over the last decade. One of the largest problems in our understanding, and ultimately in our successful treatment of gliomas is the great heterogeneity between tumors. The purpose of this study is to develop a molecular classification schema that is both clinically and biologically meaningful, based on gene expression and genomic data from tumors of patients who will be prospectively followed through the natural history and treatment phase of their illness.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: ELIGIBILITY CRITERIA: Any patient with radiographic suggestion of a primary glial neoplasm or any patient with a known glial neoplasm. Medically indicated (diagnostic and/or therapeutic) tumor resection, or biopsy. Informed consent from patient or parents of children under the age of 18 years old.
Total Enrollment: 300
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Cheryl Royce 3014026298
Additional Information:
Study ID Numbers: 020140; 02-C-0140
Study Start Date: March 1, 2002
Record last reviewed: February 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031538
Other Glioma Studies:
1. Phase I Trial and Pharmacokinetic Study of TLC D-99 in Pediatric Patients with Refractory Solid Tumors
2. A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
3. A Phase I Trial of CC-8490 for the Treatment of Patients with Recurrent/Refractory High-Grade Gliomas
4. STI571 to Treat Malignant Brain Tumors
5. A Phase I Study of 2-Chlorodeoxyadenosine and Radiation for the Treatment of High Grade Glioma (CDX)
Related Studies:
Other Glioma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Genetic Analysis of Brain Tumors
|
|
|
|
|
|
|
|
